CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Finance Lease, Right-of-Use Asset, Amortization
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Finance Lease, Right-of-Use Asset, Amortization of $3.08 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-25 was $803.00K, a 7.70% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-09-25 was $846.00K, a 12.42% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-06-26 was $840.00K, a 10.35% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-03-27 was $848.00K, a 10.83% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $3.08M, a 0.87% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $3.11M, a 13.33% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $2.75M, a 9.56% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $3.04M, a 9.05% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|---|
| 2025-12-27 | $3.08M 10-K · filed 2026-02-18 | ||||
| 2024-12-28 | $3.11M 10-K · filed 2026-02-18 | ||||
| 2023-12-30 | $2.75M 10-K · filed 2026-02-18 | ||||
| 2022-12-31 | $3.04M 10-K · filed 2025-02-19 | ||||
| 2021-12-25 | $803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $1.65M derived: sum of 2 quarters · filed 2024-02-14 | $2.49M derived: sum of 3 quarters · filed 2024-02-14 | $3.34M 10-K · filed 2024-02-14 | |
| 2021-09-25 | $846.00K 10-Q · filed 2021-11-03 | $1.69M derived: sum of 2 quarters · filed 2021-11-03 | $2.53M 10-Q · filed 2021-11-03 | $3.40M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-26 | $840.00K 10-Q · filed 2021-08-04 | $1.69M 10-Q · filed 2021-08-04 | $2.56M derived: sum of 3 quarters · filed 2023-02-22 | $3.52M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-27 | $848.00K 10-Q · filed 2021-05-04 | $1.72M derived: sum of 2 quarters · filed 2023-02-22 | $2.68M derived: sum of 3 quarters · filed 2023-02-22 | $3.62M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-26 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.84M derived: sum of 2 quarters · filed 2023-02-22 | $2.77M derived: sum of 3 quarters · filed 2023-02-22 | $3.72M 10-K · filed 2023-02-22 | |
| 2020-09-26 | $966.00K 10-Q · filed 2021-11-03 | $1.90M derived: sum of 2 quarters · filed 2021-11-03 | $2.85M 10-Q · filed 2021-11-03 | $3.94M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-06-27 | $937.00K 10-Q · filed 2021-08-04 | $1.89M 10-Q · filed 2021-08-04 | $2.97M derived: sum of 3 quarters · filed 2022-02-16 | $4.04M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2020-03-28 | $951.00K 10-Q · filed 2021-05-04 | $2.04M derived: sum of 2 quarters · filed 2022-02-16 | $3.11M derived: sum of 3 quarters · filed 2022-02-16 | $4.04M derived: sum of 4 quarters · filed 2022-02-16 | |
| 2019-12-28 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.16M derived: sum of 2 quarters · filed 2022-02-16 | $3.09M derived: sum of 3 quarters · filed 2022-02-16 | $4.01M 10-K · filed 2022-02-16 | |
| 2019-09-28 | $1.07M 10-Q · filed 2020-10-29 | $2.00M derived: sum of 2 quarters · filed 2020-10-29 | $2.92M 10-Q · filed 2020-10-29 | ||
| 2019-06-29 | $931.00K 10-Q · filed 2020-08-05 | $1.85M 10-Q · filed 2020-08-05 | |||
| 2019-03-30 | $921.00K 10-Q · filed 2020-05-07 | $921.00M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |